These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6351901)

  • 1. Comparison of ocular hypotensive effects of 3 dosages of oral atenolol.
    Tutton MK; Smith RJ
    Br J Ophthalmol; 1983 Oct; 67(10):664-7. PubMed ID: 6351901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-response study of oral atenolol administered once daily in patients with raised intra-ocular pressure.
    Stenkula E; Wettrell K
    Graefes Arch Clin Exp Ophthalmol; 1982; 218(2):96-8. PubMed ID: 7042481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.
    Myers JS; Sall KN; DuBiner H; Slomowitz N; McVicar W; Rich CC; Baumgartner RA
    J Ocul Pharmacol Ther; 2016 Oct; 32(8):555-562. PubMed ID: 27002298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure.
    Chauhan JK; Mishra YC; Khilnani K
    Indian J Ophthalmol; 1989; 37(4):179-81. PubMed ID: 2700474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment.
    Rakofsky SI; Melamed S; Cohen JS; Slight JR; Spaeth G; Lewis RA; Zbrowski-Gutman L; Eto CY; Lue JC; Novack GD
    Ophthalmology; 1989 Jan; 96(1):8-11. PubMed ID: 2645553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.
    Camras CB; Siebold EC; Lustgarten JS; Serle JB; Frisch SC; Podos SM; Bito LZ
    Ophthalmology; 1989 Sep; 96(9):1329-36; discussion 1336-7. PubMed ID: 2780003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the effectiveness and safety of levobunolol and timolol in ocular hypertension and chronic open-angle glaucoma].
    Freyler H; Novack GD; Menapace R; Skorpik C; Mordaunt J; Batoosingh AL
    Klin Monbl Augenheilkd; 1988 Sep; 193(3):257-60. PubMed ID: 3070134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
    Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of topical atenolol on intraocular pressure.
    Wettrell K; Pandolfi M
    Br J Ophthalmol; 1977 May; 61(5):334-8. PubMed ID: 326301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study.
    Berlin MS; Rowe-Rendleman C; Ahmed I; Ross DT; Fujii A; Ouchi T; Quach C; Wood A; Ward CL
    Br J Ophthalmol; 2016 Jun; 100(6):843-7. PubMed ID: 26453641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atenolol eye drops in glaucoma: a double-masked, controlled study.
    Phillips CI; Gore SM; Macdonald MJ; Cullen PM
    Br J Ophthalmol; 1977 May; 61(5):349-53. PubMed ID: 326303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
    García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
    Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.